Nicotinamide Riboside (Niagen) Proof-of-concept Study
October 17, 2023
Nicotinamide Riboside (Niagen) Proof-of-concept Study Completed Clinical Studies & Trials
Investigator:
Michel Willemsen, MD, PhD
Location:
The Netherlands
Purpose:
This 4-month open labeled, explorative trial was performed to examine certain laboratory markers and neurological symptoms, quality of life, and potential adverse effects in participants with A-T treated with nicotinamide ribose (Niagen®, ChromaDex).
Conclusions
Data analysis ongoing.